The synergistic ototoxicity of radiation and cisplatin (CDDP) has not been adequately studied. This study investigated whether the use of concurrent and postradiotherapy CDDP in patients with nasopharyngeal carcinoma (NPC) resulted in a difference in postradiotherapy sensorineural hearing when compared with the use of radiotherapy alone.
INTRODUCTION
Combined chemoradiotherapy is increasingly being used to treat advanced head and neck cancers. The ear is often included in the radiation fields, and radiation-induced sensorineural hearing loss can result.
1,2 Cisplatin (CDDP), which is widely used as an effective antineoplastic drug for these cancers, is also known to cause ototoxicity. Therefore, it is expected that the use of combined chemoradiotherapy results in greater sensorineural hearing loss than using radiotherapy alone, which was shown to be the case in several reports. [3] [4] [5] [6] [7] However, a number of other reports showed that sensorineural hearing after combined therapy was not significantly worse than after radiotherapy alone. [8] [9] [10] [11] Many of these previous reports were based on studies that were either retrospective or involved a limited number of patients, and data emanating from randomized trials were lacking. The true differences in extent, onset, and clinical course of sensorineural hearing loss between patients treated with combined chemoradiotherapy and patients treated with radiotherapy alone remain unknown. The aim of this study was to investigate the difference in postradiotherapy sensorineural hearing between patients with nasopharyngeal carcinoma (NPC) who were treated with chemoradiotherapy using CDDP versus radiotherapy alone.
PATIENTS AND METHODS

Patients
A phase III prospective randomized trial was conducted to examine the benefit of adding chemotherapy during and after a standard course of radiotherapy for patients with locally advanced NPC. 12 All patients who had International Union Against Cancer/ American Joint Committee on Cancer (1997) T3-4NxM0 or TxN2-3M0 previously untreated NPC of the WHO type II or III histology and who were medically fit to undergo chemoradiotherapy were eligible for entry onto the trial. The diagnosis of NPC was histologically confirmed on biopsy. The exclusion criteria were previous treatment for NPC, presence of distant metastases at diagnosis, and other concomitant malignant disease. Written informed consent was obtained from all patients before random assignment. The protocol was approved by the hospital's ethics committee. Patients were randomly assigned to receive either radiotherapy or chemoradiotherapy.
Treatment
All patients received standard-course radiotherapy to a dose of 70 Gy in 35 fractions, 2 Gy per fraction, using a modified Ho's technique.
13,14 Using 6-MV linear accelerators, the primary tumor of each patient was treated with two lateral opposed facial fields to 20 Gy, followed by a three-field technique (anterior facial and lateral opposed facial fields) to a total dose of 70 Gy. The neck was treated to a dose of 60 Gy, and lymph nodes were boosted with electrons for another 10 Gy. All fields were treated once daily, 5 times a week. Patients who had high cervical lymph nodes or inferior extension of the tumor toward the oropharynx were treated with a shrinking field technique, using long opposing faciocervical fields for the first 40 Gy and followed by the three-field plan for the rest of the treatment.
For patients who were allocated to the chemoradiotherapy group, three cycles of concurrent CDDP were administered on weeks 1, 4, and 7 of radiotherapy. Subsequently, a further three cycles of adjuvant chemotherapy comprising a combination of CDDP and fluorouracil were administered between weeks 11 and 19. The dose schedules for chemotherapy are listed in Table 1 .
Treatment modifications were carried out according to the following scheme. CDDP was omitted for that cycle during the concurrent radiotherapy phase if the minimum hematologic criteria were not met (absolute neutrophil count Ͼ 1,000/L and platelet count Ͼ 100,000/L). During the adjuvant phase, deferment of the chemotherapy by up to a maximum of 2 weeks was allowed if the same hematologic criteria were not met, beyond which the patient would be taken off of the trial. Substitution of CDDP with carboplatin (dose at area under the curve of 5) was allowed in the event of grade 2 or more peripheral neuropathy or intolerable emesis with CDDP. Chemotherapy was also discontinued completely in the event of patient refusal, physician's decision for fear of radiotherapy compromise, and unacceptable toxicities such as severe sepsis or renal impairment. Every effort was taken not to delay or break the course of radiotherapy.
Random Assignment
Random assignment on the trial was conducted through the central randomization office of the National Medical Research Council of Singapore, Clinical Trials and Epidemiology Research Unit, Singapore, by means of a telephone call. Patients were entered onto the trial using randomized blocks of four and six patients (stratified by nodal stage) based on a 1:1 treatment allocation. The treatment assignment was generated using a computer program.
Inclusion Criteria for the Present Report on Hearing Outcomes
The data presented in the present report were based on subsets of patients from the two arms of the trial, which accrued patients from different centers. All patients who originated from one of the centers, the Singapore General Hospital, underwent additional audiologic assessments, and the results form the basis of this report.
Audiologic Assessment
Pure-tone audiograms were performed by trained audiologic technicians who did not have prior knowledge of a patient's treatment group. Pretreatment and postradiotherapy audiograms at 1 week, 6 months, 1 year, and 2 years were obtained. The audiograms included assessment of bone conduction thresholds at 0.5, 1, 2, and 4 kHz. As in previous reports by other authors, 9,10,15 high and lower frequencies in the speech range were represented by the threshold at 4 kHz and the average of 0.5-, 1-, and 2-kHz thresholds, respectively. For each patient, the left and right hearing levels were analyzed separately.
Statistical Methods
The data were analyzed using SPSS version 11.5 (SPSS Inc, Chicago, IL). The Mann-Whitney U test was performed to compare the hearing levels between the radiotherapy and chemoradiotherapy groups at various postradiotherapy time points.
RESULTS
Fifty-seven patients were randomly assigned to the radiotherapy group, and 58 patients were randomly assigned to the chemoradiotherapy group. The age, sex, and race distributions for each group are listed in Table 2 . For the radiotherapy group, hearing thresholds for 106, 62, 46, and 30 ears could be studied at 1 week, 6 months, 1 year, and 2 years after treatment, respectively. For the chemoradiotherapy group, hearing levels for 100, 82, 48, and 42 ears could be studied at 1 week, 6 months, 1 year, and 2 years after treatment, respectively. These declining enrollments were the result of patients who declined further audiologic assessments, patients who were lost to follow-up, or patients who died from advanced disease. The median CDDP dose received by the patients was 160 mg (range, 112 to 213 mg).
Analysis Across the Two Groups
The hearing levels in the radiotherapy and chemoradiotherapy groups at different postradiotherapy time points are illustrated in Figures 1 and 2 . In the lower speech frequencies, the hearing levels were statistically significantly worse in the chemoradiotherapy group compared with the radiotherapy group at 1 year (P ϭ .001) and 2 years (P ϭ .03) after radiotherapy but not at 1 week and 6 months after radiotherapy (Table 3 ). It is notable that, even for the chemoradiotherapy group, the postradiotherapy median hearing levels remained at the upper end of normal thresholds. For 4 kHz however, hearing was significantly poorer in the chemoradiotherapy group than the radiotherapy group at all postradiotherapy time points studied. Furthermore, the magnitude of postradiotherapy hearing loss was much greater at 4 kHz than at the lower speech frequencies. This was especially pronounced in patients in the chemoradiotherapy group, highlighting the vulnerability of higher frequency hearing to the synergistic ototoxic effects of combined therapy.
Analysis Within Each of the Two Groups
Radiotherapy group. Figures 1 (hearing in the lower speech frequencies) and 2 (hearing at 4 kHz) show the median hearing thresholds following a trend over time, such that hearing loss occurring in the immediate postradiotherapy period improved within the first year. Thereafter, median hearing thresholds deteriorated again at 2 years after treatment.
Chemoradiotherapy group. In this group, the median hearing threshold deterioration, which started in the immediate postradiotherapy period, seemed to stabilize by 1 year (Figs 1 and 2) .
DISCUSSION
Radiation-induced sensorineural hearing loss has long been recognized as an important adverse effect. Early-onset sensorineural hearing loss occurs during or shortly after radiation.
1 Late-onset sensorineural hearing loss typically occurs several months or years after radiation.
2, 8 The extent of hearing loss is related to the radiation dose used. Most human studies have reported the effects over a narrow dose range (50 to 70 Gy) for a limited number of patients; the rate of permanent hearing loss ranged from 24.2% to 36% in patients receiving doses approaching 60 Gy.
5 High-frequency hearing is generally more severely affected by radiation.
2 CDDP-induced ototoxicity is also well known; is characterized by bilateral, irreversible, and progressive high tone loss; and is directly related to dose and inversely related to age. 16 Although combined chemoradiotherapy using CDDP has increasingly been used to treat advanced head and neck cancers, the synergistic ototoxic effect of radiation and CDDP has not been adequately studied.
The present study is the first randomized controlled trial that compares the effects of radiotherapy and CDDP chemoradiotherapy on sensorineural hearing. In NPC, relatively high doses of radiation are used in standard treatment regimens, and the ear structures are included in the radiation fields. In our previous study on NPC patients, we found the average minimum, maximum, and mean point doses (Ϯ standard deviation) delivered to the inner ear to be 36.2 Ϯ 11.9, 56.9 Ϯ 7.1, and 46.7 Ϯ 11.2, respectively. 17 Because the same radiotherapy technique has been used in both the previous and present studies, these radiation doses are also applicable to the patients in both arms of the present study. However, poor survival in individuals with advanced NPC is a limitation, and the relatively narrow range of radiation dose to the inner ear limits the ability to study the effects of dose on hearing in NPC patients.
Patients in the chemoradiotherapy group experienced greater sensorineural hearing damage than patients in the radiotherapy group. In animal and pathology studies, outer hair cells of the cochlea suffered pronounced damage after radiotherapy, and similar changes were observed in CDDP ototoxicity. 8 The observation in our study that higher frequency hearing was generally more affected than lower frequency hearing is consistent with findings from other clinical studies.
2,9 Higher frequency sounds were more severely affected possibly because the outer cells at the basal turn were arranged in three regular rows compared with four rows at the apex.
10 High-frequency hearing loss can have a significant impact on quality of life because it affects speech discrimination. 8 In the radiotherapy group, early post-treatment deterioration of median hearing thresholds improved within 1 year but worsened again at 2 years. Reversal of acute sensorineural hearing loss after radiation was also reported by Ho et al 15 in approximately 40% of the ears in NPC patients treated with radiotherapy. That hearing loss fluctuated during the first year in this group was the overall result of multifactorial processes that affected sensorineural hearing, including resolution of radiation-induced acute inflammatory changes. The addition of CDDP during and after radiotherapy resulted in less fluctuation.
The finding that combined CDDP-radiotherapy resulted in worse sensorineural hearing compared with radiotherapy alone was consistent with the results of a previous report by Schell et al. 3 In that study, it was found that children and young adults treated with CDDP suffered an additional 20-to 30-dB sensorineural hearing loss if they received prior cranial radiotherapy. Skinner et al 4 also reported more severe CDDP ototoxicity in patients who had previously received radiotherapy encompassing the ear. Although Merchant et al 5 observed enhanced ototoxicity in children with brain tumors treated with preradiotherapy ototoxic chemotherapy, a prospective study on 32 patients with NPC who were treated with chemoradiotherapy (where CDDP was administered before and during radiotherapy) found the incidence of sensorineural hearing loss to be similar to the incidence of patients treated with radiotherapy alone.
9 Two other studies on patients with NPC treated with chemoradiotherapy (where CDDP was administered before radiotherapy) also showed that CDDP did not have an additional adverse effect on sensorineural hearing. 8, 10 The conflicting results from most of these reports could be related to whether chemotherapy was administered before or after radiotherapy. Walker et al 16 observed enhanced ototoxicity when CDDP was administered simultaneously with radiation or after radiation and suggested that postirradiation hyperemia could be the cause of increased sensitivity of the cochlear to CDDP damage. Synergistic ototoxic effects could also result if radiation provided a predisposition to damage 18 or caused changes in permeability of the inner ear and/or CNS barriers leading to an enhanced effect of CDDP in inner ear tissues. 7 In our present study, CDDP was administered during (concurrent chemotherapy) and after (adjuvant chemotherapy) radiotherapy, which was consistent with the belief that enhanced ototoxicity would occur. With preradiotherapy administration of CDDP, the synergistic effects of CDDP and radiation might be reduced.
11
Beyond the follow-up period of this study, the post-treatment sensorineural hearing in both groups is expected to further decline over time with the onset of delayed radiation-induced hearing loss.
5,15,19 It remains to be seen how the post-treatment sensorineural hearing outcomes between the two groups will differ in the longer term because the rate and degree of deterioration may not necessarily be the same. Nevertheless, it would not be unreasonable to expect, over the longer term, for the sensorineural hearing of patients in the chemoradiotherapy group to remain significantly poorer than sensorineural hearing of patients in the radiotherapy group, possibly to an even greater extent.
This study addresses an important issue that has received little attention in the published literature. As combined chemoradiation increases in use in advanced head and neck cancers, normal tissue tolerance once defined for radiation alone should be redefined when used together with chemotherapy. According to Emami et al, 20 the tolerance dose with a probability of 5% complication within 5 years from treatment and the tolerance dose with a probability of 50% complication within 5 years from treatment of the inner ear are 60 and 70 Gy, respectively. Doses less than 30 Gy are said to have little effect on hearing. 5, 21 In light of the results of the present study, these doses may not apply in patients who have received radiotherapy combined with concurrent/ adjuvant chemotherapy.
This study demonstrated that patients with NPC who had received combined radiotherapy and concurrent/adjuvant chemotherapy using CDDP experienced greater sensorineural hearing loss compared with patients treated with radiotherapy alone, especially with respect to high-frequency sounds in the speech range. Normal inner ear tissue tolerance, which was once defined only for radiation alone, should be redefined for radiotherapy used together with chemotherapy.
